Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : Rgnx save search
REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
Published: 2024-03-05 (Crawled : 12:00) - prnewswire.com
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: 32.77%
H: 1.55%
C: -13.22%
duchenne positive trial
REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
Published: 2024-02-29 (Crawled : 22:00) - prnewswire.com
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: 2.41%
H: 21.44%
C: 18.65%
duchenne trial
REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial
Published: 2024-02-07 (Crawled : 12:00) - prnewswire.com
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: 3.52%
H: 14.66%
C: 7.85%
duchenne positive trial
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
Published: 2024-01-16 (Crawled : 20:00) - prnewswire.com
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: -0.49%
H: 3.17%
C: 1.94%
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -7.15%
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.94%
rgx-314 aaviate positive treatment trial
REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial
Published: 2023-11-29 (Crawled : 12:00) - prnewswire.com
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: 0.42%
H: 3.03%
C: -3.58%
duchenne trial
REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published: 2023-11-03 (Crawled : 23:00) - prnewswire.com
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
| Email alert
Add to watchlist
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
| Email alert
Add to watchlist
rgx-314 altitude year one positive treatment trial diabetic
REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society
Published: 2023-10-03 (Crawled : 20:00) - prnewswire.com
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: 2.06%
H: 1.01%
C: -9.98%
rgx-202 congress world international trial
REGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial Updates
Published: 2023-06-27 (Crawled : 11:00) - prnewswire.com
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: 0.27%
H: 7.36%
C: 6.61%
day pipeline trial
Diabetic Retinopathy Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 50 Key Companies Working in the Domain | DelveInsight
Published: 2023-05-29 (Crawled : 15:00) - prnewswire.com
KOD | News | $3.37 1.2% 1.19% 340K
|
Health Technology
| Email alert
Add to watchlist
OPT | News | $3.46 2.98% 2.89% 8.2K
|
Health Technology
| Email alert
Add to watchlist
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
| Email alert
Add to watchlist
companies pipeline space trial diabetic
Additional Positive Interim Data from Phase I/II Trial of REGENXBIO'S RGX-111 for the Treatment of Severe MPS I Presented at WORLDSymposium™
Published: 2023-02-24 (Crawled : 21:00) - biospace.com/
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: -1.43%
H: 0.98%
C: -0.37%
rgx-111 treatment trial positive
Additional Positive Interim Data from Phase I/II/III CAMPSIITE™ Trial of REGENXBIO's RGX-121 for the Treatment of MPS II (Hunter Syndrome) Presented at 19th Annual WORLDSymposiumTM
Published: 2023-02-22 (Crawled : 20:00) - prnewswire.com
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: 0.72%
H: 0.47%
C: -2.78%
rgx-121 treatment trial positive
REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients
Published: 2023-01-23 (Crawled : 13:00) - biospace.com/
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: -1.52%
H: 1.37%
C: 0.09%
rgx-202 candidate active trial duchenne therapy
REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I
Published: 2022-12-08 (Crawled : 13:00) - biospace.com/
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: 0.45%
H: 2.13%
C: 0.22%
rgx-111 treatment trial mps-ih mps-i
REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published: 2022-11-03 (Crawled : 12:00) - biospace.com/
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: -3.01%
H: 0.77%
C: -10.46%
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: 0.74%
H: 11.76%
C: 7.35%
rgx-314 altitude treatment expansion trial positive diabetic
REGENXBIO to Host Conference Call on November 3 to Discuss Third Quarter 2022 Financial Results, Recent Operational Highlights and Interim Data from Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy
Published: 2022-10-27 (Crawled : 12:20) - biospace.com/
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: 1.18%
H: 1.81%
C: -2.24%
rgx-314 altitude treatment conference trial financial diabetic
REGENXBIO Presents Additional Positive Interim Data from the Phase I/II/III CAMPSIITE™ Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
Published: 2022-08-31 (Crawled : 18:00) - biospace.com/
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: 2.64%
H: 0.8%
C: -3.81%
rgx-121 treatment symposium trial positive study mps-ih
REGENXBIO Announces Enrollment Complete in Cohort 5 of Phase II AAVIATE® Trial
Published: 2022-07-08 (Crawled : 12:20) - biospace.com/
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: -1.77%
H: 2.6%
C: 2.14%
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: 0.66%
H: 13.07%
C: 13.07%
aaviate trial
REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published: 2022-02-12 (Crawled : 20:20) - prnewswire.com
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
| Email alert
Add to watchlist
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
| Email alert
Add to watchlist
rgx-314 treatment liver trial positive diabetic diabetes
REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium™ 2022
Published: 2022-02-09 (Crawled : 17:00) - prnewswire.com
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: 3.58%
H: 1.42%
C: 0.62%
rgx-111 treatment symposium trial positive mps-ih mps-i
REGENXBIO Announces FDA Clearance of IND for Clinical Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy
Published: 2022-01-06 (Crawled : 13:00) - biospace.com/
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: 0.94%
H: 1.03%
C: -1.47%
rgx-202 fda muscular dystrophy clearance gene therapy trial fda clearance duchenne therapy
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.